Nonetheless, the frequent development of SMO inhibitor resistance (discussed in Section 3.1.1) in advanced BCC still warrants the development of new GLI inhibitors and investigation of their potential use as second-line therapy in clinical settings. This evidence concerns the gene GLI1 and skin basal cell carcinoma.